CAMBRIDGE, Mass., Oct. 28, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today presented the first preclinical proof-of-concept data on STAR0602, its novel TCR agonist antibody, during the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA) in Barcelona, Spain. The data presented showed potent anti-tumor activity

ROCKVILLE, Md., Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA, from November 2-5, 2022. The Company will host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarte

Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD, a finding that could provide insights into how genetics can make someone more susceptible to developing PTSD following trauma exposure. The study, published October 20 in Nature Neuroscience, is the first to use induced pluripotent stem cell models to study PTSD. It was conducted by a team of scientists from the Icahn School of Me

NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of ag

BRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that an abstract highlighting the progress of the Quatramer-based Ferroptosis Inducer, HSB-1216, are available as a poster at the 34th EORTC- NCI - AACR Symposium (ENA 2022) in Ba

CAMBRIDGE, Mass. – October 17, 2022–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) today presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD), at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria. This was the first time the SKYLARK Study was presented at a medical congress. Zuranolone is an investigational therapy being evaluated as a

SAN DIEGO, Oct. 13, 2022 /PRNewswire/ -- Neurelis, Inc., today announced findings from a novel, investigational analysis of the time between seizure clusters in pediatric patients using VALTOCO® (diazepam nasal spray). Findings indicate a significant increase in these intervals, or SEIzure interVAL (SEIVAL) data, over a 12-month period. This data will be presented at the 51st Child Neurology Society Annual Meeting in Cincinnati, Ohio, Oct. 12-15, 2022. VALTOCO, a nasal spray for acute treatment

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targ

SECAUCUS, N.J., Oct. 11, 2022 /PRNewswire/ -- More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Published today in the Journal of Clinical Oncology (JCO) Clinical Cancer Informati